Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
维亚生物维亚生物(HK:01873) Prnewswire·2025-12-15 14:06

STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US1.5billionintotaltransactionvalue,includinganupfrontpaymentatclosingofUS1.5 billion in total transaction value, including an upfront payment at closing of US950 million, subject to customary adjustments, and contingent consideration of up to US$550 million. The transaction is exp ...